prior chemotherapy and/or IFN/IL2 based immunotherapy for metastatic disease;

prior malignancies within past 5 years, with the exception of cured non-melanoma skin cancer, or in situ cancer of cervix;

clinically significant cardiovascular disease;

ongoing treatment with aspirin (\>325mg/day) or other medications known to predispose to gastrointestinal ulceration.

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma